ONCOARENDI THERAP ZY-01
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more
ONCOARENDI THERAP ZY-01 (1B1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, ONCOARENDI THERAP ZY-01 (1B1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ONCOARENDI THERAP ZY-01 - Net Assets Trend (None–None)
This chart illustrates how ONCOARENDI THERAP ZY-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ONCOARENDI THERAP ZY-01 (None–None)
The table below shows the annual net assets of ONCOARENDI THERAP ZY-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to ONCOARENDI THERAP ZY-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
ONCOARENDI THERAP ZY-01 Competitors by Market Cap
The table below lists competitors of ONCOARENDI THERAP ZY-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ES SUNLOGY BERHAD
KLSE:0345
|
$21.16 Million |
|
CLOUD TECHNOL.AB ZY -10
F:42T
|
$21.17 Million |
|
PT Satu Visi Putra Tbk
JK:VISI
|
$21.17 Million |
|
Phoenix New Media Limited
NYSE:FENG
|
$21.17 Million |
|
Telescope Innovations Corp.
PINK:TELIF
|
$21.14 Million |
|
Cosmos Yatirim Holding AS
IS:COSMO
|
$21.13 Million |
|
Bexil Cp
PINK:BXLC
|
$21.12 Million |
|
Lay Hong Bhd
KLSE:9385
|
$21.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ONCOARENDI THERAP ZY-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares ONCOARENDI THERAP ZY-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently ONCOARENDI THERAP ZY-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares ONCOARENDI THERAP ZY-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ONCOARENDI THERAP ZY-01 (1B1) | €- | N/A | N/A | $21.15 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |